Wikipedia mirror

Jens Kuhle

Jens Kuhle is a Swiss/German neurologist, clinical researcher, and professor specialising in multiple sclerosis (MS) and neuroimmunology. He is Head of the Multiple Sclerosis Centre and Vice Head of the Department of Neurology at the University Hospital Basel (USB) and a research group leader in Clinical Neuroimmunology at the University of Basel.[1][2]

Education

Kuhle studied medicine at the Eberhard-Karls University in Tübingen, where he obtained his medical degree (MD).[3] He completed specialist training in neurology and neuroimmunology at the University Hospital Basel. He subsequently undertook doctoral research (PhD) in neuroimmunology at Queen Mary University of London.[4]

Career

After completing his PhD, Kuhle returned to Basel, where he became a research group leader in clinical neuroimmunology within the Departments of Clinical Research and Biomedicine. He later served as Deputy Head of the Outpatient Clinic and the Multiple Sclerosis Centre at the University Hospital Basel. He was subsequently appointed Head of the Multiple Sclerosis Centre and, in 2021, assumed leadership of the Neuroimmunology Unit. His clinical role includes senior consultant responsibilities at the Department of Neurology of the University Hospital Basel.[5]

He was appointed Clinical Professor of Neuroimmunology at the University of Basel as part of a newly established professorship, jointly held with Tobias Derfuss.[6][7]

Kuhle initiated and leads the Swiss Multiple Sclerosis Cohort (SMSC), a nationwide, prospective, multicentre research network designed to collect longitudinal clinical, imaging, and biospecimen data from people with MS.[8] The cohort supports research on disease mechanisms, biomarkers, and treatment outcomes.[9][10]

Research

Kuhle’s research focuses on the identification and validation of biomarkers for disease activity, progression, and treatment response in multiple sclerosis.[11][12] His group pioneered and importantly contributed to the clinical establishment of serum neurofilament light chain (NfL) as a biomarker of neuroaxonal injury in MS measurable in blood. In addition, his group investigates glial fibrillary acidic protein (GFAP) as a marker of astrocytic pathology associated with disease progression.[13][14] More recently, his research has expanded to the systematic investigation of biomarker panels in highly characterised clinical cohorts, integrating longitudinal clinical data, imaging, and biospecimens to improve biological stratification and risk assessment in multiple sclerosis.[15][16]

Selected publications

  • Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study (The Lancet Neurology).[17]
  • Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis (JAMA Neurology).[18]
  • Intrathecal immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis (Annals of Neurology).[19]
  • Swiss Multiple Sclerosis Cohort (SMSC): prospective cohort study of clinical and imaging biomarkers (clinical cohort publications).[20]

References

  1. ^ "Kuhle Jens | Department of Biomedicine | University of Basel". biomedizin.unibas.ch. Retrieved 2026-02-02.
  2. ^ "Jens Kuhle". VJNeurology. Retrieved 2026-02-02.
  3. ^ "'Usual suspect' lesions appear not to cause most severe disability in MS patients". www.buffalo.edu. Retrieved 2026-02-02.
  4. ^ "Jens Kuhle - RC2NB". Retrieved 2026-02-02.
  5. ^ Sutter, Markus. "Der Biomarker NfL verspricht für die Zukunft noch einiges". Medical Tribune Schweiz (in Swiss High German). Retrieved 2026-02-03.
  6. ^ "Tobias Derfuss and Jens Kuhle Professors of Neuroimmunology and Multiple Sclerosis". medizin.unibas.ch. 2025-02-13. Retrieved 2026-02-02.
  7. ^ "Two doctors to share professorship at newly created Research Center". www.unibas.ch. Retrieved 2026-02-02.
  8. ^ Khalil, Michael; Pirpamer, Lukas; Hofer, Edith; Voortman, Margarete M.; Barro, Christian; Leppert, David; Benkert, Pascal; Ropele, Stefan; Enzinger, Christian; Fazekas, Franz; Schmidt, Reinhold; Kuhle, Jens (2020-02-10). "Serum neurofilament light levels in normal aging and their association with morphologic brain changes". Nature Communications. 11 (1): 812. doi:10.1038/s41467-020-14612-6. ISSN 2041-1723. PMC 7010701.
  9. ^ https://pubmed.ncbi.nlm.nih.gov/35182510
  10. ^ Meglio, Marco (2026-02-03). "Glial Fibrillary Acidic Protein Represents Valuable Biomarker for MS Disease Progression | NeurologyLive - Clinical Neurology News and Neurology Expert Insights". www.neurologylive.com. Retrieved 2026-02-03.
  11. ^ https://universe.unibas.ch/org-units/94/research-groups/181/overview
  12. ^ "Serum Neurofilament Light Chain Levels in Patients with Presymptomatic Multiple Sclerosis". Uniformed Services University. Retrieved 2026-02-03.
  13. ^ https://www.scilit.com/scholars/17400547
  14. ^ "Neurology® Journals". Neurology® Journals. Retrieved 2026-02-03.
  15. ^ "Sage Journals: Discover world-class research". Sage Journals. Retrieved 2026-02-03.
  16. ^ Leppert, David; Kropshofer, Harald; Häring, Dieter; Dahlke, Frank; Patil, Ashwini; Meinert, Rolf; Tomic, Davorka; Kappos, Ludwig; Kuhle, Jens (2022-10-04). "Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials". Neurology. 99 (14): 631–631. doi:10.1212/WNL.0000000000201277. ISSN 0028-3878.
  17. ^ Benkert, Pascal; Meier, Stephanie; Schaedelin, Sabine; Manouchehrinia, Ali; Yaldizli, Özgür; Maceski, Aleksandra; Oechtering, Johanna; Achtnichts, Lutz; Conen, David; Derfuss, Tobias; Lalive, Patrice H.; Mueller, Christian; Müller, Stefanie; Naegelin, Yvonne; Oksenberg, Jorge R. (2022-03-01). "Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study". The Lancet Neurology. 21 (3): 246–257. doi:10.1016/S1474-4422(22)00009-6. ISSN 1474-4422. PMID 35182510.
  18. ^ Benkert, Pascal; Maleska Maceski, Aleksandra; Schaedelin, Sabine; Oechtering, Johanna; Zadic, Amar; Vilchez Gomez, Juan Francisco; Melie‐Garcia, Lester; Cagol, Alessandro; Galbusera, Riccardo; Subramaniam, Suvitha; Lorscheider, Johannes; Galli, Edoardo; Mueller, Jannis; Fischer‐Barnicol, Bettina; Achtnichts, Lutz (2024-10-16). "Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis". Annals of Neurology. 97 (1): 104–115. doi:10.1002/ana.27096. ISSN 0364-5134. PMC 11683165. PMID 39411917. Archived from the original on 2025-08-01.
  19. ^ https://pmc.ncbi.nlm.nih.gov/articles/PMC8518907/
  20. ^ "Swiss Multiple Sclerosis Cohort study". PubMed.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.